4//SEC Filing
OSBORNE DAVID W 4
Accession 0001567619-22-006229
CIK 0001787306other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 4:18 PM ET
Size
5.8 KB
Accession
0001567619-22-006229
Insider Transaction Report
Form 4
OSBORNE DAVID W
Chief Technical Officer
Transactions
- Sale
Common Stock
2022-03-01$17.75/sh−775$13,758→ 246,982 total
Footnotes (4)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Shares and RSUs remain subject to a lock-up agreement with the underwriters for the Issuer's follow-on offering in February 2021.
- [F2]The transaction was executed in multiple trades in prices ranging from $17.40 to $18.185, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 1,004 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as follows: 976 shares on May 31, 2021 and 28 shares on November 30, 2021.
- [F4]Includes 14,000 RSUs.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001252999
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 4:18 PM ET
- Size
- 5.8 KB